Novartis (NOVN.S), will acquire Tourmaline Bio (TRML.O), for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.
September 9, 2025 - 14:50
By Pharos Investment Advisors Comments are Off
Novartis (NOVN.S), will acquire Tourmaline Bio (TRML.O), for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved